776 related articles for article (PubMed ID: 30784124)
1. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
Barlebo Ahlborn L; Østrup O
APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
3. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
4. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C; Birkbak NJ; Swanton C
Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
[TBL] [Abstract][Full Text] [Related]
5. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries.
Alcaide M; Rushton C; Morin RD
Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047
[TBL] [Abstract][Full Text] [Related]
6. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
9. [Circulating Tumor DNA (ctDNA) Detection Using BEAMing and Its Clinical Significance.].
Nakamura K
Rinsho Byori; 2016 May; 64(4):400-406. PubMed ID: 29182806
[TBL] [Abstract][Full Text] [Related]
10. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of circulating tumor DNA in breast cancer.
Chan JCH; Chow JCH; Ho CHM; Tsui TYM; Cho WC
J Cancer Res Clin Oncol; 2021 May; 147(5):1431-1442. PubMed ID: 33760943
[TBL] [Abstract][Full Text] [Related]
12. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Liquid Biopsy in Precision Oncology Research.
Sato Y; Matoba R; Kato K
Biol Pharm Bull; 2019; 42(3):337-342. PubMed ID: 30828064
[TBL] [Abstract][Full Text] [Related]
14. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA: A Step into the Future of Cancer Management.
Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
[TBL] [Abstract][Full Text] [Related]
16. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy: unlocking the potentials of cell-free DNA.
Chu D; Park BH
Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
[TBL] [Abstract][Full Text] [Related]
18. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
Valpione S; Campana L
Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.
Gorgannezhad L; Umer M; Islam MN; Nguyen NT; Shiddiky MJA
Lab Chip; 2018 Apr; 18(8):1174-1196. PubMed ID: 29569666
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA as a post-treatment surveillance strategy: current status.
Burgener JM; Rostami A; De Carvalho DD; Bratman SV
Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
